China
Amanda Yang and Rachel Tan at Rouse and Landy Jiang at Lusheng Law Firm provide an overview of the draft amendments to China’s trademark law
Chunguang Hu of China PAT explains why his ‘insider’ experience as a patent examiner benefits clients and why he wants to debunk the myth that IP has limited value in China
From AI and the UPC to troublesome trademarks in China, experts name the IP trends likely to dominate 2026
The Australian side, in particular, can benefit by capitalising on its independent status to bring in more work from Western countries while still working with its former Chinese partner
Recently published Special Focus articles
Recently published Special Focus articles
-
Sponsored by Tahota Law FirmCharles Feng of Tahota Law Firm concludes a two-part series on intellectual property protection in China by looking at copyright, unfair competition, and a change to the appeals procedure for technology-related disputes -
Sponsored by Wanhuida Intellectual PropertyWu Xiaohui of Wanhuida Intellectual Property explains why a recent decision on inventiveness assessments of co-solvent compound crystals heralds a significant shift in focus by the CNIPA, with implications for pharmaceutical patent strategies
-
Sponsored by Tahota Law FirmIn the first article of a two-part series, Charles Feng, Lian Xue, and Runjing Wang of Tahota Law Firm consider the different perspectives on whether China’s Anti-Unfair Competition Law should regulate internet advertising blocking
-
Sponsored by Tahota Law FirmA two-part series concludes with Charles Feng, Lian Xue, and Runjing Wang of Tahota Law Firm analysing relevant Chinese case law in assessing whether the mobile application LiTiaotiao constitutes unfair competition
-
Sponsored by Liu, Shen & AssociatesXuelan Yue of Liu Shen & Associates draws on several ‘model cases’ put forward by the Intellectual Property Court of the Supreme People’s Court of China to highlight trends in trade secret infringement cases
-
Sponsored by Wanhuida Intellectual PropertyA ruling on the inventiveness of a compound patent for a prostate cancer therapeutic could help create uniform jurisprudence regarding the examination of pharmaceutical patents, says Guan Yue of Wanhuida Intellectual Property
